Amwins Global Risks

The team at Amwins will be supporting us through the Blood Cancer UK Matthew Wilson Multiple Myeloma Fund with all monies raised being focused on beating this particular type of blood cancer.

Together as a community, our ambition is to cure multiple myeloma. Through investing in science and scientists, this fund will improve treatments, survival rates and quality of life for people living with multiple myeloma and drive forward the day when we find a cure.

Multiple myeloma is a type of blood cancer that affects around 5,000 people in the UK every year. For most people, myeloma responds well to initial treatment but unfortunately it almost always comes back.

The fund has already led to the funding of two clinical research fellows, who through the pursuit of a PhD could become research leaders in multiple myeloma. One of the fellows' research projects will focus on gaining further understanding into how key molecules help myeloma cells to grow and thrive.

The other research project will focus on developing new screening tools and drugs.

To find out more about the partnership efforts, why not take a look at our press release?

We’re joining forces with Amwins Global Risks because Matthew and the whole blood cancer community need us. As a team, we will get to a day when no one dies from blood cancer or its treatments.